MarketCapExport financials
Biodesix (BDSX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Biodesix Income Statement 2025-2011 | BDSX
Brief overview of revenue and earnings at Biodesix
The conclusions below are based on five years of reported results. According to figures from Biodesix, revenue changed from 45.6 million dollars to 88.5 million dollars over five years. The five-year change reached +94.3%, while CAGR stood at 14.2%. The company expanded its sales base at a healthy rate.
The operating result measured by EBITDA moved from −20 million dollars to −22.2 million dollars, or −10.8%. The operating result developed less favorably than sales. At the operating-margin level, the figure shifted from −44% to −25.1%. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −$65.4 million to −$35.3 million. The loss narrowed, although sustainable profitability has not yet returned.
Conclusion
The figures do not all move in the same direction. The financial profile benefits from sales growth, a stronger final result and higher operating efficiency. The most visible risks are a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Biodesix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
113 M | 4.59 M | 132 M | 72.8 M | 145 M | 97.5 M | - | - | - | - | - | - | - | - | - |
Shares |
7.55 M | 6.47 M | 82.1 M | 42.1 M | 27.4 M | 4.84 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
14.9 | 0.71 | 1.61 | 1.73 | 5.29 | 20.2 | - | - | - | - | - | - | - | - | - |
Net Income |
-35.3 M | -42.9 M | -52.1 M | -65.4 M | -43.2 M | -65.4 M | -30.7 M | -26.2 M | - | - | - | - | - | - | - |
Revenue |
88.5 M | 71.3 M | 49.1 M | 38.2 M | 54.5 M | 45.6 M | 24.6 M | 20.4 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 18.5 M | 16 M | - | - | - | - | - | - | - |
Operating Income |
-27.9 M | -34.5 M | -41.3 M | -50.6 M | -40.9 M | -22.9 M | -26.7 M | - | - | - | - | - | - | - | - |
Interest Expense |
7.72 M | 8.26 M | 9.54 M | 8.07 M | 4.51 M | 7.6 M | 3.01 M | - | - | - | - | - | - | - | - |
EBITDA |
-22.2 M | -28.7 M | -38 M | -47 M | -37.8 M | -20 M | -19.8 M | -16.3 M | - | - | - | - | - | - | - |
Operating Expenses |
116 M | 106 M | 90.4 M | 88.8 M | 95.4 M | 45.7 M | 41.1 M | 34.1 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
87.5 M | 80.5 M | 67.4 M | 61.5 M | 50.5 M | 34.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Biodesix
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10.3 M | 9.66 M | 7.5 M | 147 M | 147 M | 7.27 M | 7.32 M | 127 M | 97.2 M | 96.2 M | 79.7 M | 78.5 M | 77.8 M | 77.6 M | 40.4 M | 39.2 M | 31.1 M | 30.8 M | 28.1 M | 27.7 M | 26.6 M | 26.6 M | 277 K | 275 K | 261 K | 255 K | 244 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-7.27 M | -7.79 M | -8.72 M | -11.5 M | -11.1 M | - | -10.3 M | -10.8 M | -13.6 M | - | -10.9 M | -13.4 M | -18.7 M | - | -13.7 M | -15.8 M | -15.6 M | - | -11.5 M | -11.4 M | -6.96 M | - | -8.84 M | -8.27 M | -9.71 M | - | -9.6 M | -6.86 M | -7.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
26.9 M | 25.6 M | 21.8 M | 20 M | 18 M | - | 18.2 M | 17.9 M | 14.8 M | - | 13.5 M | 11.9 M | 9.06 M | - | 11.1 M | 11 M | 6.55 M | - | 6.53 M | 11.9 M | 28.9 M | - | 9.19 M | 4.24 M | 5.1 M | - | 3.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-5.39 M | -6.2 M | -7.05 M | -9.72 M | -9.14 M | - | -8.59 M | -8.24 M | -11 M | - | -7.17 M | -10.9 M | -16.4 M | - | -10.6 M | -11.6 M | -14.5 M | - | -13.1 M | -10.6 M | -5.58 M | - | -6.24 M | -5.62 M | -8.42 M | - | -9.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.98 M | 1.98 M | 2.07 M | 1.9 M | 1.68 M | - | 2.04 M | 1.94 M | 2.53 M | - | 2 K | 2.43 M | 2.39 M | - | 3.04 M | 1.35 M | 1.14 M | - | 1.55 M | 815 K | 651 K | - | 2.66 M | 2.78 M | 1.46 M | - | 706 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-4 M | -4.8 M | -5.64 M | -8.28 M | -7.7 M | - | -7.1 M | -6.82 M | -9.6 M | - | -6.87 M | -10.6 M | -15.6 M | - | -10.2 M | -11.2 M | -13.6 M | - | -10.8 M | -10.4 M | -4.84 M | - | -4.07 M | -4.23 M | -7.74 M | - | -6.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
32.2 M | 31.8 M | 28.8 M | 29.7 M | 27.1 M | - | 26.7 M | 26.2 M | 25.8 M | - | 20.7 M | 22.8 M | 25.4 M | - | 21.7 M | 22.6 M | 21 M | - | 19.6 M | 22.5 M | 34.4 M | - | 15.4 M | 9.86 M | 13.5 M | - | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
24.3 M | 24.3 M | 21.7 M | 22.4 M | 20.4 M | - | 20 M | 19.7 M | 20.6 M | - | 15.5 M | 16.7 M | 19 M | - | 15.1 M | 15.2 M | 14.5 M | - | 13.6 M | 11.4 M | 11.9 M | - | 7.88 M | 6.83 M | 8.08 M | - | 8.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Biodesix (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
Irlanda
Britain
Germany
China
Australia
Schweiz
